MiMedx Group (MDXG) to Release Earnings on Tuesday

MiMedx Group (NASDAQ:MDXG) is scheduled to announce its earnings results after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $86.83 million during the quarter, compared to analyst estimates of $85.58 million. MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Stock Performance

Shares of MDXG opened at $6.27 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.11 and a current ratio of 3.57. The stock has a market capitalization of $925.33 million, a P/E ratio of 19.59 and a beta of 1.32. The company’s fifty day moving average is $7.47 and its two-hundred day moving average is $7.56. MiMedx Group has a 1 year low of $3.53 and a 1 year high of $9.27.

Analysts Set New Price Targets

Several equities analysts have issued reports on MDXG shares. Lake Street Capital started coverage on shares of MiMedx Group in a research note on Thursday, March 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Mizuho boosted their price objective on shares of MiMedx Group from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $12.25.

Insider Transactions at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 20,381 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total transaction of $162,028.95. Following the transaction, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at approximately $3,815,674.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CAO William Frank Iv Hulse sold 20,381 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total transaction of $162,028.95. Following the transaction, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at approximately $3,815,674.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Ricci S. Whitlow sold 15,493 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $8.07, for a total transaction of $125,028.51. Following the completion of the sale, the chief operating officer now directly owns 416,321 shares in the company, valued at $3,359,710.47. The disclosure for this sale can be found here. Insiders have sold a total of 51,145 shares of company stock valued at $409,378 in the last ninety days. 19.90% of the stock is currently owned by company insiders.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.